| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 7785- | ISL, | Enhancement of Oral Bioavailability and Anti-hyperuricemic Activity of Isoliquiritigenin via Self-Microemulsifying Drug Delivery System |
| - | in-vivo, | Nor, | NA |
| 7741- | isoFl, | Lyco, | SIL, | Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement |
| - | Trial, | Pca, | NA |
| 7740- | isoFl, | Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial |
| - | Trial, | Pca, | NA |
| 7739- | isoFl, | Soy, red clover, and isoflavones and breast cancer: a systematic review |
| - | Review, | BC, | NA |
| 7738- | isoFl, | Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced pro-inflammatory cytokines and immune suppressive cells |
| - | Trial, | Pca, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7885- | isoO, | Isoorientin from Gypsophila elegans induces apoptosis in liver cancer cells via mitochondrial-mediated pathway |
| - | in-vitro, | Liver, | HepG2 |
| 7822- | isoO, | Isoorientin Affects Markers of Alzheimer's Disease via Effects on the Oral and Gut Microbiota in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 7850- | ISQ, | Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study |
| - | Trial, | Nor, | NA |
| - | in-vivo, | Nor, | NA |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7791- | ISQ, | Isoquercitrin: pharmacology, toxicology, and metabolism |
| - | Review, | Nor, | NA |
| 7841- | ISQ, | Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease |
| - | Human, | CardioV, | NA |
| 7837- | ISQ, | Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation |
| - | in-vivo, | Nor, | NA |
| 7844- | ISQ, | Isoquercetin upregulates antioxidant genes, suppresses inflammatory cytokines and regulates AMPK pathway in streptozotocin-induced diabetic rats |
| - | in-vivo, | Diabetic, | NA |
| 7559- | ISQ, | Difference in absorption of the two structurally similar flavonoid glycosides, hyperoside and isoquercitrin, in rats |
| - | in-vivo, | Nor, | NA |
| 7986- | itraC, | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma |
| - | Trial, | BCC, | NA |
| 7991- | itraC, | A Phase II Trial of Perioperative Oral Itraconazole for the Management of Low-Risk Basal Cell Carcinoma |
| - | Trial, | BCC, | NA |
| 7990- | itraC, | A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial |
| - | Trial, | Ovarian, | NA |
| 7989- | itraC, | Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer |
| - | Trial, | NSCLC, | NA |
| 7987- | itraC, | Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer |
| - | Trial, | Pca, | NA |
| 8013- | itraC, | High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer |
| - | Case Report, | Pca, | NA |
| 8016- | itraC, | Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma |
| - | Human, | Ovarian, | NA |
| 8015- | itraC, | Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth |
| - | vitro+vivo, | BCC, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8047- | IVM, | The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug |
| - | Review, | Var, | NA |
| 8042- | IVM, | Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug |
| - | vitro+vivo, | Var, | NA |
| - | in-vitro, | Lung, | A549 |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| 7896- | IVT, | VT, | Molecular targets of vitexin and isovitexin in cancer therapy: a critical review |
| - | Review, | Var, | NA |
| 7898- | IVT, | Pharmacokinetics and tissue distribution study of Isovitexin in rats by HPLC-MS/MS |
| - | in-vivo, | Nor, | NA |
| 7819- | JG, | Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes |
| - | vitro+vivo, | Nor, | NA |
| 1917- | JG, | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
| - | in-vitro, | AML, | HL-60 |
| 4005- | K+, | Potassium |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA |
| 4011- | K+, | Sodium and potassium intakes among US adults: NHANES 2003–2008 |
| - | Analysis, | Nor, | NA |
| 8101- | KAE, | Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway |
| - | vitro+vivo, | ESCC, | KYSE150 | - | vitro+vivo, | ESCC, | Eca109 |
| 8103- | KAE, | The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions |
| - | in-vitro, | HCC, | HUH7 |
| 8071- | KAE, | Cellular reprogramming and signaling control by kaempferol in colorectal cancer |
| - | Review, | CRC, | NA |
| 8058- | KAE, | A randomized, placebo‐controlled trial evaluating the safety of excessive administration of kaempferol aglycone |
| - | Trial, | Nor, | NA |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8063- | KAE, | Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways |
| - | in-vitro, | Ovarian, | NA |
| 8064- | KAE, | Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | SNU-213 |
| 8074- | KAE, | Dose-dependent tuning of HSP70-Beclin-1 by kaempferol governs autophagy and chemosensitivity |
| - | in-vitro, | SCC, | KYSE150 | - | in-vitro, | SCC, | KYSE450 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
| 8079- | KAE, | Endoplasmic Reticulum Stress-Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Cerv, | HeLa |
| 8080- | KAE, | Hepatoprotective Effect of Kaempferol—A Review |
| - | Review, | Nor, | NA |
| 7827- | KAE, | MBS, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA |
| - | Trial, | Nor, | NA |
| 8110- | L-Orn, | L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism |
| - | Trial, | Nor, | NA |
| - | Trial, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid